Wedbush reaffirmed their buy rating on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a report released on Monday morning, TipRanks reports. Wedbush currently has a $26.00 price target on the stock.
Other equities research analysts also recently issued reports about the company. Zacks Investment Research upgraded Allena Pharmaceuticals from a hold rating to a buy rating and set a $0.75 target price on the stock in a report on Wednesday, March 18th. Credit Suisse Group reiterated a hold rating and set a $4.00 target price on shares of Allena Pharmaceuticals in a report on Monday, February 17th. B. Riley dropped their target price on Allena Pharmaceuticals from $11.00 to $7.00 and set a buy rating on the stock in a report on Friday, March 13th. Finally, Roth Capital dropped their target price on Allena Pharmaceuticals from to in a report on Wednesday, March 18th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Allena Pharmaceuticals presently has an average rating of Buy and an average target price of $9.75.
Allena Pharmaceuticals stock opened at $0.97 on Monday. The stock’s 50-day moving average is $1.77 and its 200-day moving average is $2.87. The company has a market cap of $23.39 million, a price-to-earnings ratio of -0.45 and a beta of 1.80. The company has a debt-to-equity ratio of 0.35, a current ratio of 3.03 and a quick ratio of 3.03. Allena Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $7.31.
Allena Pharmaceuticals (NASDAQ:ALNA) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Research analysts anticipate that Allena Pharmaceuticals will post -1.26 EPS for the current year.
Several large investors have recently made changes to their positions in ALNA. Algert Global LLC purchased a new stake in shares of Allena Pharmaceuticals during the 4th quarter valued at about $101,000. Banco Bilbao Vizcaya Argentaria S.A. acquired a new stake in Allena Pharmaceuticals during the 4th quarter valued at approximately $104,000. Wedbush Securities Inc. grew its stake in Allena Pharmaceuticals by 95.5% during the 4th quarter. Wedbush Securities Inc. now owns 50,150 shares of the company’s stock valued at $137,000 after purchasing an additional 24,500 shares in the last quarter. Geode Capital Management LLC grew its stake in Allena Pharmaceuticals by 103.0% during the 4th quarter. Geode Capital Management LLC now owns 105,854 shares of the company’s stock valued at $288,000 after purchasing an additional 53,719 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Allena Pharmaceuticals by 91.2% during the 4th quarter. Renaissance Technologies LLC now owns 241,700 shares of the company’s stock valued at $660,000 after purchasing an additional 115,300 shares in the last quarter. Institutional investors and hedge funds own 58.42% of the company’s stock.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Recommended Story: Most Volatile Stocks – What Investors Need to Know to Maximize ROI
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.